(Press-News.org) A newly developed molecule, LK-2, could inform new therapies for stroke-related brain injury, finds scientists at The Hospital for Sick Children (SickKids).
An ischemic stroke occurs when blood flow to a part of the brain is interrupted, depriving the brain cells of oxygen and nutrients. Without timely treatment, brain cells can die, resulting in permanent damage to the brain and its functions. Stroke is one of the leading causes of death and disability worldwide, affecting millions every year.
An international study published in Nature co-led by Dr. Lu-Yang Wang, a Senior Scientist in the Neurosciences & Mental Health program at SickKids, and clinician scientists at the Shanghai Jiao Tong University School of Medicine, has uncovered a molecule that holds the potential to protect neurons during stroke and prevent stroke-related brain damage.
“Our findings provide an entirely new way to think about saving cells while minimizing the adverse neural side effects of conventional stroke therapy,” says Wang, who holds a Tier 1 Canada Research Chair in Brain Development and Disorders. “The LK-2 molecule could be the key to unlocking successful therapeutics for stroke patients.”
How one neurotransmitter is contributing to stroke-related brain damage
One of the main culprits behind stroke-induced brain damage is a neurotransmitter called glutamate. When the brain is starved of oxygen and sugar, glutamate levels rise dramatically, overstimulating N-methyl-Daspartate receptors (NMDARs) on the membrane of brain cells. This causes a surge of calcium to enter cells, triggering a cascade of events that ultimately leads to cell death.
For decades, researchers have tried to develop drugs that can block NMDARs and prevent the neurotoxicity that comes with elevated levels of glutamate. However, previous drugs targeting NMDARs have been ineffective and failed to move beyond clinical trials because NMDARs play important roles in regular brain functions, such as learning and memory. In addition, blocking NMDARs completely can cause serious side effects, such as psychosis and cognitive impairment.
The team found that glutamate can also bind to and activate a type of acidosis sensor called acid-sensing ion channels (ASICs), which are normally activated by acids. ASICs are present in the membrane of brain cells – like NMDARs – and can allow calcium ions to enter the cells when stimulated.
“We have shown that glutamate can supercharge the activity of ASICs, especially under the acidic conditions that occur during stroke,” explains Wang. “This means that glutamate is attacking brain cells through both NMDARs and ASICs – something we did not know before now.”
A new way to block excess glutamate
By identifying the specific site in ASICs where glutamate binds, the team was able to develop a new molecule, called LK-2, that can selectively block the glutamate binding site in ASICs, but leave NMDARs intact.
In preclinical models, the team found that LK-2 effectively prevented glutamate from overstimulating ASICs to reduce the flow calcium and cell death. Furthermore, LK-2 did not affect NMDARs or other regular neural transmissions, which suggests its potential as the next generation of stroke therapeutics.
“Our research has revealed a new way to protect the brain from glutamate toxicity without interfering with NMDARs,” Wang says.
Wang’s research will continue to explore the function and mechanisms of LK-2, in the hopes of developing future clinical trials.
The research team wants to thank Dr. Julie Forman-Kay, a Senior Scientist and Program Head of the Molecular Medicine program, and Dr. Iva Pritišanac, a postdoctoral fellow in Forman-Kay’s lab, who assisted Wang in locating the binding sites for glutamate on ASICs.
This research is funded at SickKids by the Canadian Institutes of Health Research (CIHR), the Natural Sciences and Engineering Research Council of Canada (NSERC) and Canada Research Chair Program. For a full list of funders, access the paper in Nature.
END
The molecule that could alleviate stroke-related brain injury
2024-07-10
ELSE PRESS RELEASES FROM THIS DATE:
Scientists discover a cause of lupus and a possible way to reverse it
2024-07-10
· Lupus is an autoimmune disease affecting more than 1.5 million people in the U.S.
· Until now, the causes of this disease remained unclear
· Scientists are working to expand research into novel treatment
CHICAGO --- Northwestern Medicine and Brigham and Women’s Hospital scientists have discovered a molecular defect that promotes the pathologic immune response in systemic lupus erythematosus (known as lupus) and show that reversing this defect may potentially reverse the disease.
Lupus affects more than 1.5 million ...
Few U.S. adults use nicotine pouches, study finds
2024-07-10
A new study found that the prevalence of nicotine pouch use was low in U.S. adults despite a 641% increase in sales of the products between 2019 and 2022. Researchers say the findings raise questions about who is using the millions of nicotine pouches sold in the U.S. and why.
Nicotine pouches, a new commercial tobacco product, contain a crystalline powder with nicotine, flavorings (including fruit, mint or candy) and other additives. They do not cause respiratory harm and are perceived by some as an alternative to help adults who smoke tobacco quit. ...
Surprise discovery with big scientific potential
2024-07-10
An unexpected find has enabled important progress to be made in the battle against harmful bacteria.
An international team of researchers, led by Professor Peter Fineran from the University of Otago, investigated a particular protein used by bacteria-infecting viruses, known as phages.
Research into this microscopic arms race between bacteria and phages is important as it can lead to alternatives to antibiotics.
Published in prestigious international journal Nature, the study analysed a protein phages use when deploying anti-CRISPR, their method of blocking the CRISPR–Cas immune system of bacteria.
Lead ...
The plague may have caused the downfall of the Stone Age farmers
2024-07-10
Ancient DNA from bones and teeth hints at a role of the plague in Stone Age population collapse. Contrary to previous beliefs, the plague may have diminished Europe's populations long before the major plague outbreaks of the Middle Ages, new research shows.
In the 14th century Europe, the plague ravaged the population during the so-called 'Black Death,' claiming the lives of nearly a third of the population.
But the plague arrived in Scandinavia several thousand years earlier, and despite several theories suggesting otherwise, the plague might have caused an epidemic, according to new research from ...
When there’s money to lose, phone usage while driving drops
2024-07-10
PHILADELPHIA— To make someone put their phone down while driving, show them the money—with a catch, according to new research published in JAMA Open. When a group of auto insurance customers were tempted with a cash incentive—and regular feedback letting the driver know how they were doing compared to other drivers trying to reduce their phone time—handheld phone use dropped significantly, a team at the Perelman School of Medicine at the University of Pennsylvania found.
The researchers examined several different strategies ...
Astronomers find missing link in massive black hole formation
2024-07-10
Omega Centauri is a spectacular collection of 10 million stars, visible as a smudge in the night sky from Southern latitudes. Through a small telescope, it looks no different from other so-called globular clusters; a spherical stellar collection so dense towards the center that it becomes impossible to distinguish individual stars. But a new study, led by researchers from the University of Utah and the Max Planck Institute for Astronomy, confirms what astronomers had argued about for over a decade: Omega Centauri contains a central black hole. The black hole appears to be the missing link between its stellar ...
Researchers build first-ever molecular atlas of blood vessel pathways in the human brain, across early brain development, adulthood and disease
2024-07-10
An international consortium of researchers led by University Health Network (UHN) in Toronto and University of Zurich have built the first-ever molecular atlas of the human brain vasculature at single-cell resolution, spanning from early development to adulthood and through disease stages such as brain tumours and brain vascular malformations.
The international consortium includes research teams from UHN’s Krembil Brain Institute, Donald K. Johnson Eye Institute, Toronto General Hospital Research Institute and Princess Margaret Cancer Centre, the University of Toronto’s Donnelly Centre, Mount Sinai Hospital’s Lunenfeld-Tanenbaum ...
Antiferromagnetic phase transition observed in fermionic Hubbard quantum simulator
2024-07-10
In a study published online in Nature, a research team led by Prof. PAN Jianwei, Prof. CHEN Yuao, and Prof. YAO Xingcan from the University of Science and Technology of China (USTC) of the Chinese Academy of Sciences has, for the first time, observed the antiferromagnetic phase transition within a large-scale quantum simulator of the fermionic Hubbard model (FHM). This study highlights the advantages of quantum simulation. It marks an important first step towards obtaining the low-temperature phase diagram of the FHM and understanding the role of quantum magnetism in the mechanism of high-temperature ...
A drug that lowers blood lipids could help treat the world’s most common liver disease
2024-07-10
The University of Barcelona has led a study that suggests using the drug known as pemafibrate to treat liver disease associated with metabolic disorders, the most common liver pathology in the world, which affects one in four people. The drug has long been marketed in Japan for another use: improving blood lipid levels in patients with hyperlipidaemia, a common condition in diabetics. Now, however, it could help address this serious liver disease, which still has no specific treatment.
The study, carried out on laboratory animal models and published in the journal Biomedicine & Pharmacotherapy, was conducted by a team led by Professor Juan ...
Ochsner, AJMC® partner for conference on value-based care on July 25 in New Orleans
2024-07-10
NEW ORLEANS – Ochsner Health’s Healthy State initiative, in partnership with The American Journal of Managed Care, will host a free conference on value-based care from 3:30-7 p.m. on Thursday, July 25 at The Westin New Orleans hotel in Louisiana.
Registration and program details are available here for “Healthy State: Know It, Own It, Live It: Creating a Thriving Louisiana Through Innovation in Value-Based Care.” The event is open to the public, medical professionals, health policy experts and community organizers.
Organized ...